Boceprevir Study Doubles Hepatitis C Clearance Rate
Share
Follow Us
The Editors at Hepatitis Central
November 11, 2009
Learn about a phase II trial, whereby Boceprevir was added to standard Hepatitis C therapy (pegylated interferon and ribavirin) and was twice as effective at eliminating the Hep C virus compared to standard therapy alone.
Schering hep C drug promising in Phase II study
By Bill Berkrot
NEW YORK, Nov 1 (Reuters) – The addition of Schering-Plough Corp’sSGP.N experimental hepatitis C drug boceprevir after four weeks of treatment with standard medicines led to highly encouraging sustained response rates in a mid-stage study.
The triple combination of boceprevir and the current treatments of pegylated-interferon and ribavirin appeared to knock out the virus at double the rate of the standard drugs alone, according to researchers.
Continue reading the entire article:
http://www.reuters.com/article/rbssHealthcareNews/idUSN3043814620091101
